Literature DB >> 8559356

Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study.

B M van Geel1, J H Koelman, P G Barth, B W Ongerboer de Visser.   

Abstract

Adrenomyeloneuropathy (AMN) is one of the most frequent phenotypes of X-linked adrenoleukodystrophy. Whether the polyneuropathy in AMN results from primary demyelination or axonal degeneration is uncertain. We examined 23 patients (18 men with AMN and five female carrier with AMN symptomatology), performed electroneurography and EMG, and compared our results with standardized electrodiagnostic criteria for primary demyelination. Both clinically and electrodiagnostically, the lower extremities were most frequently and most severely affected. A longer duration of symptoms was related to more severe pyramidal dysfunction (p < 0.004) and spasticity (p < 0.04), and to a more severe impairment of vibration sense (p < 0.05). There were on correlations between the different electrophysiologic studies and the duration of neurologic symptoms. Only two AMN patients (9%) fulfilled the electrodiagnostic criteria for primary demyelination. However, both had abnormally low compound muscle action potentials, which may have been a reflection of primary axonal degeneration. Six other patients (26%) partially fulfilled the criteria for primary demyelination, of whom five also manifested low compound muscle action potentials. In 15 patients (65%), we found polyneuropathy with predominantly axonal, sensorimotor features. We conclude that the neuropathy in AMN patients is due to primary axonal degeneration.

Entities:  

Mesh:

Year:  1996        PMID: 8559356     DOI: 10.1212/wnl.46.1.112

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Granny trips down: is she carrying the big bad wolf?

Authors:  L Tremolizzo; M Patassini; G Uziel; B Castellotti; C Gellera; C Ferrarese; I Appollonio
Journal:  Neurol Sci       Date:  2012-05-17       Impact factor: 3.307

Review 4.  X-linked adrenoleukodystrophy: pathogenesis and treatment.

Authors:  Marc Engelen; Stephan Kemp; Bwee-Tien Poll-The
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

Review 5.  Therapeutic strategies in adrenoleukodystrophy.

Authors:  Bela R Turk; Ann B Moser; Ali Fatemi
Journal:  Wien Med Wochenschr       Date:  2017-05-10

6.  Nerve conduction studies in adrenomyeloneuropathy.

Authors:  V Chaudhry; H W Moser; D R Cornblath
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

Review 7.  The clinical spectrum of X-linked adrenoleukodystrophy: from Addison's-only in men to middle-age neurologic manifestations in women.

Authors:  Lúcia Fadiga; Miguel Melo; Joana Saraiva; Isabel Paiva
Journal:  Hormones (Athens)       Date:  2021-10-15       Impact factor: 2.885

Review 8.  Therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser
Journal:  NeuroRx       Date:  2006-04

Review 9.  Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.

Authors:  Stephan Kemp; Irene C Huffnagel; Gabor E Linthorst; Ronald J Wanders; Marc Engelen
Journal:  Nat Rev Endocrinol       Date:  2016-06-17       Impact factor: 43.330

10.  X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.

Authors:  Marc Engelen; Stephan Kemp; Marianne de Visser; Björn M van Geel; Ronald J A Wanders; Patrick Aubourg; Bwee Tien Poll-The
Journal:  Orphanet J Rare Dis       Date:  2012-08-13       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.